carbohydr
bind
agent
cba
includ
natur
lectin
consid
broadspectrum
antivir
molecul
abl
directli
inhibit
mani
virus
human
immunodefici
viru
hiv
hepat
c
viru
hcv
dengu
viru
ebola
viru
sever
acut
respiratori
syndrom
coronaviru
bind
envelop
protein
nglycan
case
hiv
shown
cba
select
mutant
virus
nglycosyl
site
delet
sensit
neutral
antibodi
studi
aim
evalu
hcv
resist
cba
vitro
hcv
cultiv
presenc
increas
galanthu
nivali
agglutinin
gna
cyanovirinn
concanavalina
griffithsin
concentr
eight
week
end
lectin
exposur
genom
isol
strain
sequenc
sever
potenti
resist
mutat
envelop
glycoprotein
identifi
effect
mutat
viral
fit
well
sensit
inhibit
lectin
solubl
neutral
antibodi
assess
surprisingli
none
mutat
alon
combin
confer
resist
cba
contrast
observ
mutant
sensit
inhibit
addit
sever
mutat
identifi
core
nonstructur
protein
thu
result
suggest
contrast
hiv
hcv
resist
cba
directli
confer
mutat
envelop
protein
gene
could
occur
indirect
mechan
involv
mutat
viral
protein
investig
need
complet
elucid
underli
mechan
hepat
c
viru
hcv
small
posit
singlestrand
rna
viru
belong
hepaciviru
genu
flavivirida
famili
envelop
viru
infect
hepatocyt
caus
seriou
liver
diseas
human
past
treatment
hcv
includ
use
interferon
ribavirin
combin
effect
well
toler
howev
new
era
final
start
thank
develop
directact
antivir
arsen
enabl
achiev
sustain
virolog
respons
treat
patient
clinic
trial
nevertheless
concern
remain
access
care
lowto
middleincom
countri
viral
resist
could
encount
reallif
lesscompli
popul
hcv
entri
hepatocyt
complex
multistep
process
involv
viral
envelop
glycoprotein
sever
cell
entri
factor
includ
srbi
ocln
two
envelop
glycoprotein
present
surfac
viral
particl
larg
coval
complex
stabil
disulfid
bridg
glycoprotein
heavili
nglycosyl
result
one
third
molecular
mass
heterodim
correspond
nglycan
inde
nglycosyl
site
conserv
sequenc
genotyp
shown
major
site
harbor
highmannosetyp
glycan
even
egress
viral
particl
cell
addit
contribut
demonstr
correspond
nglycan
play
import
role
function
protein
enabl
correct
fold
envelop
protein
ii
modul
effici
entri
step
iii
mask
conserv
neutral
epitop
envelop
glycoprotein
close
bind
site
cellular
receptor
featur
make
hcv
nglycan
promis
target
new
antivir
strategi
highmannos
glycan
rare
present
cellular
protein
exit
endoplasm
reticulum
proof
concept
provid
vitro
vivo
use
sever
lectin
cyanovirinn
griffithsin
scytovirin
well
nonpeptid
carbohydr
bind
agent
cba
pradimicina
howev
potenti
resist
hcv
therapeut
strategi
never
investig
studi
sought
evalu
vitro
resist
hcv
cba
end
cultiv
hcv
strain
presenc
increas
concentr
differ
lectin
galanthu
nivali
agglutinin
gna
cyanovirinn
cvn
concanavalina
cona
griffithsin
grft
sever
week
sequenc
genom
isol
strain
sever
potenti
resist
mutat
identifi
character
revers
genet
describ
previous
obtain
transduct
cell
lentiviru
pseudoparticl
encod
report
protein
rfpnlsip
cell
grown
co
dulbecco
modifi
essenti
medium
dmem
gibco
supplement
fetal
bovin
serum
cona
gna
purchas
sigma
purifi
cvn
kindli
provid
k
gustafson
nation
institut
health
nation
cancer
institut
frederick
md
usa
grft
kindli
provid
k
e
palmer
owensboro
cancer
research
program
owensboro
kentucki
usa
solubl
recombin
form
larg
extracellular
loop
produc
glutathion
stransferas
fusion
protein
describ
previous
monoclon
antibodi
mab
kindli
provid
j
mckeat
univers
birmingham
unit
kingdom
mab
produc
vitro
use
miniperm
apparatu
heraeu
recommend
manufactur
neutral
assay
mab
purifi
use
pierc
protein
g
plu
agaros
recommend
manufactur
pierc
mab
antiactin
purchas
millipor
use
plasmid
encod
genom
modifi
version
fulllength
strain
genotyp
genbank
access
number
kindli
provid
wakita
nation
institut
infecti
diseas
tokyo
japan
contain
mutat
lead
amino
acid
chang
cterminu
core
protein
increas
viral
titer
construct
sequenc
encod
residu
tsssymvtndc
ntermin
region
also
modifi
reconstitut
epitop
ssglyhvtndc
previous
describ
addit
character
mutat
revers
genet
use
plasmid
encod
genom
refer
wildtyp
wt
studi
contain
renilla
luciferas
report
gene
two
adapt
mutat
respect
describ
previous
plasmid
use
produc
hcv
rna
vitro
transcript
electropor
cell
previous
describ
supernat
electropor
cell
recov
filter
membran
aliquot
store
use
cell
incub
h
differ
concentr
gna
cvn
cona
grft
viabil
measur
use
luminesc
cell
viabil
assay
recommend
manufactur
promega
infect
stock
hcv
strain
design
stock
presenc
effect
concentr
gna
cvn
cona
grft
respect
infect
cell
subcultur
administr
lectin
concentr
cell
infect
supernat
recov
use
infect
naiv
cell
presenc
lectin
escal
lectin
concentr
well
time
point
virus
recov
use
infect
naiv
cell
depict
fig
total
cellular
rna
extract
use
rneasi
kit
qiagen
hcv
rna
quantif
perform
realtim
rtpcr
assay
previous
describ
hcv
rna
supernat
extract
use
qiaamp
viral
rna
mini
kit
qiagen
hcv
genom
sequenc
determin
directli
sequenc
overlap
purifi
rtpcr
fragment
bigdy
termin
kit
appli
biosystem
sequenc
primer
use
rtpcr
sequenc
reaction
avail
request
use
quickchang
ii
xl
site
direct
mutagenesi
kit
agil
technolog
introduc
potenti
resist
mutat
plasmid
encod
genom
note
wt
studi
nucleotid
sequenc
mutant
verifi
replic
infect
assess
measur
renilla
luciferas
activ
use
renilla
luciferas
assay
system
promega
berthold
lb
luminomet
inhibit
assay
perform
preincub
hcvcc
lectin
mab
h
put
contact
target
cell
h
contact
hcvcc
cell
incub
h
complet
medium
luciferas
activ
measur
indic
manufactur
promega
mann
whitney
test
use
indic
valu
p
p
consid
threshold
signific
order
studi
viral
resist
cba
cultiv
hcv
vitro
presenc
increas
concentr
differ
highmannos
specif
lectin
gna
cvn
cona
grft
took
advantag
cell
line
enabl
monitor
hcv
infect
live
cell
first
infect
cell
presenc
effect
concentr
lectin
gna
cvn
cona
grft
respect
infect
cell
subcultur
everi
three
four
day
presenc
lectin
cell
infect
soon
cell
infect
supernat
recov
use
infect
naiv
cell
presenc
lectin
concentr
lectin
increas
stepwis
manner
describ
fig
condit
abl
propag
hcv
presenc
gna
three
month
cvn
two
month
highest
possibl
cona
concentr
due
toxic
drug
cell
cultur
higher
concentr
fig
remark
difficult
propag
viru
presenc
grft
suggest
adapt
hcv
lectin
challeng
confirm
isol
cba
resist
strain
compar
sensit
isol
strain
parent
strain
lectin
shown
fig
observ
strain
isol
presenc
gna
cvn
grft
less
sensit
lectin
parent
strain
contrast
strain
isol
presenc
cona
seem
sensit
parent
strain
cona
analys
envelop
gene
hcv
strain
isol
upon
escal
gna
cvn
cona
grft
exposur
identifi
mutat
select
hcv
envelop
protein
gene
cultur
presenc
lectin
sequenc
genom
region
encompass
end
core
end
three
mutat
identifi
three
month
cultur
gna
interestingli
mutat
expect
prevent
addit
nglycan
nglycosyl
site
posit
introduc
prolin
residu
asparagin
serin
mutat
found
cultur
hcv
presenc
cvn
cona
grft
interestingli
also
identifi
mutat
three
virus
isol
cultur
lectin
three
mutat
also
detect
virus
select
cvn
cona
grft
respect
mutat
previous
shown
lead
shift
nglycan
importantli
viru
passag
absenc
lectin
detect
mutat
mutat
summar
bold
charact
tabl
use
european
hepat
c
viru
databas
euhcvdb
observ
mutat
occur
residu
highli
conserv
genotyp
hcv
sequenc
also
sequenc
genotyp
tabl
sequenc
three
synonym
mutat
identifi
one
end
core
two
gna
exposur
altogeth
result
suggest
posit
select
occur
hcv
envelop
protein
gene
presenc
lectin
also
support
cumul
behavior
dsdn
ratio
obtain
use
synonym
nonsynonym
analysi
program
http
wwwhivlanlgovcontentsequencesnapsnaphtml
compar
four
sequenc
obtain
lectin
exposur
control
sequenc
obtain
cultur
without
lectin
fig
studi
effect
mutat
viru
fit
introduc
modifi
genom
express
renilla
luciferas
report
gene
revers
genet
sinc
mutat
fix
three
independ
lectin
exposur
also
decid
character
mutat
introduc
alon
combin
replicationdefect
viru
carri
mutat
gdd
motif
gnd
variant
genom
carri
larg
infram
delet
code
region
known
inactiv
viral
particl
releas
use
neg
control
replic
assembl
respect
first
assess
impact
mutat
hcv
rna
replic
shown
fig
individu
mutat
combin
two
mutat
led
slight
variat
replic
measur
luciferas
activ
h
electropor
increas
replic
observ
h
mutant
wt
respect
p
contrast
mutant
show
slight
decreas
replic
wt
p
howev
combin
three
mutat
signific
effect
replic
compar
wt
wt
confirm
mutat
lead
impedi
asparagin
nglycosyl
fig
addit
detect
mutant
contain
substitut
often
weaker
wt
residu
involv
epitop
mab
use
western
blot
character
mutant
infecti
viru
product
measur
h
postelectropor
mutant
compar
wt
supernat
cell
electropor
mutant
use
neg
control
determin
background
level
luciferas
activ
shown
fig
product
infecti
viru
mutant
significantli
decreas
compar
wt
wt
p
p
respect
contrari
result
suggest
combin
two
mutat
posit
modul
infect
product
infecti
viral
particl
markedli
improv
mutant
wt
p
p
respect
howev
differ
combin
three
mutat
found
end
select
signific
effect
infecti
viral
particl
product
order
determin
whether
mutat
select
upon
lectin
exposur
confer
resist
lectin
perform
dose
respons
curv
compar
abil
lectin
inhibit
wt
hcvcc
mutant
contain
combin
three
mutat
shown
fig
observ
combin
three
mutat
confer
resist
lectin
select
gna
cvn
cona
grft
respect
also
analyz
effect
simpl
mutat
combin
two
mutat
sensit
inhibit
lectin
way
evid
resist
confer
mutat
select
upon
gna
cvn
cona
exposur
alon
combin
two
fig
result
obtain
mutant
surpris
sinc
low
concentr
grft
also
test
sensit
four
tripl
mutant
inhibit
lectin
observ
equal
sensit
cvn
cona
grft
fig
contrast
notic
mutant
sensit
gna
inhibit
fig
combin
mutat
led
reduct
effect
concentr
requir
halfmaxim
inhibit
compar
wt
respect
sinc
mutat
identifi
upon
lectin
exposur
affect
nglycosyl
envelop
protein
known
protect
bind
site
neutral
antibodi
also
investig
mutant
sensit
neutral
mab
solubl
form
larg
extracellular
loop
shown
fig
observ
mutant
sensit
neutral
wt
inhibit
compar
wt
wherea
mutant
resist
inhibit
addit
notic
mutant
slightli
sensit
inhibit
wt
inhibit
compar
wt
fig
analys
core
nonstructur
protein
gene
hcv
strain
isol
upon
escal
gna
cvn
cona
grft
exposur
explain
viru
succeed
propag
presenc
lectin
hypothes
mutat
improv
viru
fit
modifi
properti
viral
particl
could
fix
upon
lectin
exposur
reason
sequenc
region
encod
core
nonstructur
protein
strain
isol
upon
lectin
exposur
enabl
us
identifi
sever
addit
mutat
upon
gna
cvn
cona
grft
exposur
respect
mutat
present
nonbold
charact
tabl
interestingli
similar
mutat
posit
alreadi
identifi
group
cell
cultur
adapt
sever
mutat
shown
benefici
viru
particular
assembl
process
furthermor
cumul
behavior
dsdn
ratio
fig
also
evidenc
region
encod
end
essenti
cell
cultur
adapt
posit
select
altogeth
result
suggest
hcv
resist
cba
directli
confer
mutat
envelop
protein
gene
could
occur
indirect
mechan
involv
mutat
viral
protein
investig
need
complet
elucid
mechan
hcv
resist
cba
studi
aim
evalu
resist
hcv
cba
vitro
eight
week
hcv
cultur
presenc
increas
concentr
differ
lectin
identifi
sever
mutat
genom
isol
strain
evidenc
posit
select
code
region
consequ
nonsynonym
mutat
mutat
also
detect
region
encod
core
nonstructur
protein
isol
strain
second
region
posit
select
correspond
end
region
known
frequent
mutat
cell
cultur
adapt
character
mutat
alon
combin
evidenc
none
mutat
confer
resist
cba
importantli
similar
experi
perform
presenc
neutral
mab
escap
mutat
observ
earli
day
post
treatment
sever
explan
put
forward
explain
differ
hcv
resist
mab
cba
firstli
import
note
bring
mani
conserv
nglycan
thu
mani
cba
target
shown
play
import
role
differ
step
hcv
life
cycl
moreov
notic
contrast
neutral
antibodi
cba
abl
inhibit
cell
free
well
cell
cell
transmiss
final
also
propos
lectin
could
act
viral
cellular
glycan
interact
case
human
immunodefici
viru
hiv
propos
cbabas
therapeut
strategi
could
directli
inhibit
virus
also
induc
partial
loss
glycan
shield
make
virus
vulner
attack
immun
system
interestingli
observ
even
resist
mutat
could
evidenc
hcv
envelop
glycoprotein
posit
select
occur
led
modif
hcv
glycan
shield
inde
among
identifi
mutat
amino
acid
chang
prevent
nglycosyl
asparagin
residu
correspond
glycosyl
site
import
hcv
particl
assembl
infect
well
protect
neutral
use
neutral
mab
confirm
mutat
render
viral
particl
sensit
neutral
also
identifi
mutat
previous
thoroughli
character
mutat
relat
mutat
describ
adapt
mutat
enhanc
entri
process
vitro
studi
mutat
respons
increas
infect
signific
mutat
also
known
lead
shift
nglycan
prevent
recognit
residu
sever
neutral
antibodi
observ
neutral
mab
interestingli
dose
respons
curv
use
singl
doubl
tripl
mutant
suggest
mutat
also
respons
increas
sensit
gna
fig
data
shown
sinc
gna
bind
mannos
termini
lactosamin
structur
present
highmannos
hybridand
complextyp
nglycan
increas
sensit
may
caus
differ
nglycan
matur
instead
better
access
nglycan
gna
could
explain
featur
interestingli
result
reveal
mutat
may
critic
overal
architectur
also
increas
sensit
gna
fig
data
shown
howev
caution
must
taken
mutat
confer
lectin
resist
increas
sensit
neutral
antibodi
may
fix
vivo
presenc
humor
immun
thu
contrast
hiv
seem
unlik
develop
hcv
resist
cba
would
result
enhanc
neutral
immun
system
recent
approv
sever
directact
antivir
inhibit
hcv
protein
cba
gener
viral
entri
inhibitor
unlik
find
indic
hcv
treatment
best
may
use
prevent
graft
reinfect
hcvinfect
liver
transplant
patient
possibl
treatment
hcvhiv
coinfect
patient
drug
interact
antiretrovir
frequent
observ
howev
import
featur
cbabas
therapeut
strategi
broad
antivir
spectrum
particular
cba
shown
effici
inhibit
sever
emerg
virus
dengu
viru
ebola
viru
sever
acut
respiratori
syndrom
coronaviru
knowledg
viral
resist
cba
evalu
use
hiv
strain
character
evolv
glycan
shield
thu
result
bring
new
insight
develop
cbabas
antivir
strategi
sinc
suggest
hcv
resist
cba
directli
confer
mutat
envelop
protein
gene
could
occur
indirect
mechan
involv
mutat
viral
protein
investig
need
complet
elucid
underli
mechan
